27311-63-3

Usage

Uses

Used in Chemical Synthesis:
1-Isoquinolinemethanol is used as a building block for the synthesis of various organic compounds due to its reactive functional groups and structural features.
Used in Pharmaceutical Research:
1-Isoquinolinemethanol is used as a starting material or intermediate in the development of pharmaceutical compounds, particularly those targeting the central nervous system or other biological processes.
Used in Biochemical Research:
1-Isoquinolinemethanol is used as a research tool in biochemical studies to investigate its interactions with enzymes, receptors, or other biomolecules, contributing to the understanding of biological processes and the development of new therapeutic agents.
Safety Considerations:
1-Isoquinolinemethanol should be handled with care, as it can be harmful if ingested or if it comes into contact with the skin or eyes. Appropriate safety measures, such as wearing protective clothing and using proper containment, should be taken during its use.

InChI:InChI=1/C10H9NO/c12-7-10-9-4-2-1-3-8(9)5-6-11-10/h1-6,12H,7H2

Upstream product

• 34456-69-4 [1,2,3]triazolo[5,1-a]isoquinoline 
• 119-65-3 isoquinoline 
• 107-21-1 ethylene glycol 
• 486-73-7 1-isoquinolinecarboxylic acid 
• 109-99-9 tetrahydrofuran 
• 67-56-1 methanol 
• 50-00-0 formaldehyd 
• 844-25-7 2-benzoyl-1-cyano-1,2-dihydroisoquinoline 
• 27104-72-9 methyl isoquinoline-1-carboxylate 
• 50458-78-1 ethyl isoquinoline-1-carboxylate 
• 4494-18-2 isoquinoline-1-carbaldehyde 

Downstream Products

• 4494-18-2 isoquinoline-1-carbaldehyde 
• 1721-93-3 1-methylisoquinoline 
• 66948-16-1 rac-2-(isoquinolin-1-yl)-1-phenylethan-2-ol 
• 153758-56-6 (1,2,3,4-tetrahydroisoquinolin-1-yl)methanol 
• 74417-44-0 1-(bromomethyl)isoquinoline 
• 27311-65-5 1-chloromethyl-isoquinoline 

Relevant academic research and scientific papers

PIFA-Mediated Cross-Dehydrogenative Coupling of N-Heteroarenes with Cyclic Ethers: Ethanol as an Efficient Promoter

Ethanol is typically used in organic synthesis as an environmentally benign solvent. Herein, we report a mild and efficient cross-dehydrogenative coupling (CDC) reaction of N-heteroarenes with cyclic ethers by uncovering the new reactivity of ethanol as an efficient promoter in PIFA-mediated radical process. The reaction proceeds smoothly under the irradiation of visible light and features excellent functional group compatibility, which allows the expedite synthesis of a variety of medicinally valuable Cα-heteroarylated cyclic ethers in moderate to high yields.

Carbon nitride as a heterogeneous visible-light photocatalyst for the Minisci reaction and coupling to H2 production

Cyanamide functionalised carbon nitride powder is reported as a photocatalyst for direct Minisci-type coupling of heteroarenes with ethers, alcohols, and amides using atmospheric oxygen as the oxidant at room temperature. This mild protocol displays broad substrate scope, good functional group tolerance and the catalyst can be easily isolated and reused for several cycles. It thereby addresses the two major limitations of previously reported photoredox-mediated Minisci reactions: (i) use of expensive and potentially harmful non-recyclable photocatalysts, and (ii) requirement of a stoichiometric amount of strong chemical oxidant. Finally, using platinum as a co-catalyst with the carbon nitride allows this light-mediated reaction to generate two value-added products under an anaerobic atmosphere-functionalised heteroarenes and H2 fuel.

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6

Heteroarylation of Ethers, Amides, and Alcohols with Light and O2

An efficient protocol for the Cα-H heteroarylation of ethers, amides, and alcohols using air and light under mild conditions is described. The reaction is applicable to a wide spectrum of functional groups. The generation of C-radicals via photoinduced aerobic oxidation of ethers, amides, and alcohols is the key feature of the process. Control experiments suggest a radical pathway for the reaction.

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

BIS1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR USES AS PHARMACEUTICALS

Use of Bis 1,2,3,4-tetrahydroisoquinoline derivatives represented by formula (I) as SK channel blockers and for the preparation of a medicament useful for the treatment of disorders of the central nervous system.

Samarium-promoted coupling of pyridine-based heteroaryl analogues of benzylic acetates with carbonyl compounds

(Chemical Equation Presented) 2-Substituted pyridine, quinoline, isoquinoline, bipyridine, and 1,10-phenanthroline analogues of benzylic acetates undergo Sml2-promoted coupling with aldehydes and ketones to afford (2-hydroxyalkyl)heteroaromatics.

A new, convenient, highly selective free-radical hydroxymethylation of heteroaromatic bases by persulfate oxidation of ethylene glycol and glycerol, catalysed by AgNO3

A new, convenient and selective source of hydroxymethyl ( .CH2OH) radical has been developed by persulfate oxidation of ethylene glycol with AgNO3 catalysis. The .CH 2OH radical is selectively trapped

COMPOUNDS WITH BRIDGEHEAD NITROGEN PART 74. NMR SPECTRA AND STEREOCHEMISTRY OF 1,3,10,10a-TETRAHYDRO-5H-OXAZOLOISOQUINOLINE AND 1,5,6,10b-TETRAHYDRO-3H-OXAZOLOISOQUINOLINE

Whereas 1,3,10,10a-tetrahydro-5H-oxazoloisoquinoline adopts an equilibrium in CDCl3 solution at 295 K in which the trans-fused conformation predominates, 1,5,6,10b-tetrahydro-3H-oxazoloisoquinoline adopts the O-inside cis-fused conformation.This difference in conformational preference has been explained partly in terms of ring-fusion strain.